The success of bortezomib in MM therapy can be partially attributed to its ability to promote osteoblast differentiation in MM [47] and with this is mind, the effects of Fzr on osteoblast function in the MM setting warrants investigation. The gene discussed is FZR1; the disease is Miyoshi myopathy.